Showing results (1461-1470 of 1,560) with videos related to

Sort By:
Pageof 156
Minerva Urology and Nephrology|November 17, 2020
Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndromeArcangelo Sebastianelli, Simone Morselli, Pietro Spatafora, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|August 12, 2021
Psychological Consequences Among Residents and Fellows During the COVID-19 Pandemic in New York City: Implications for Targeted InterventionsCarly A Kaplan, Chi C Chan, Jordyn H Feingold, et al.
European Urology Focus|October 14, 2019
Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational TrialArcangelo Sebastianelli, Pietro Spatafora, Jacopo Frizzi, et al.
Controlled Clinical Trials|April 12, 2003
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trialOliver M Bautista, John W Kusek, Leroy M Nyberg, et al.
Biochemical Pharmacology|December 8, 2011
Thiadiazolidinones: a new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureusMihai Ciustea, Sara Mootien, Adriana E Rosato, et al.
European Urology|February 5, 2013
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptomsClaudius Füllhase, Christopher Chapple, Jean-Nicolas Cornu, et al.
Prostate Cancer and Prostatic Diseases|May 27, 2023
Functional and oncological outcomes after radical prostatectomy in patients with history of surgery for lower urinary tract symptoms related to benign prostatic enlargement: A systematic review with meta-analysisMassimiliano Creta, Celeste Manfredi, Davide Arcaniolo, et al.
Frontiers in Psychiatry|January 3, 2022
Viloxazine in the Treatment of Attention Deficit Hyperactivity DisorderAmber N Edinoff, Haseeb A Akuly, John H Wagner, et al.
Restorative Neurology and Neuroscience|May 10, 2011
Intraventricular encapsulated calf adrenal chromaffin cells: viable for at least 500 days in vivo without detectable adverse effects on behavioral/cognitive function or host immune sensitization in ratsM D Lindner, M A Plone, B Frydel, et al.
Bulletin of Experimental Biology and Medicine|March 13, 2021
Photodynamic Therapy of Sarcoma M-1 in Rats with Photosensitizer Photoran E6O B Abramova, V V Yuzhakov, M A Kaplan, et al.
Pageof 156